Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 30, 2013, Pages

  Hanson, Kirsten K ^a   Ressurreicao, Ana S ^b   Buchholz, Kathrin ^c   Prudencio, Miguel ^a   Herman Ornelas, Jonathan D ^c   Rebelo, Maria ^a   Beatty, Wandy L ^d   Wirth, Dyann F ^c   Hanscheid, Thomas ^a   Moreira, Rui ^b   Marti, Matthias ^c   Mota, Maria M ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Host parasite interactions; Malaria; P. falciparum; Protein trafficking

Indexed keywords

ATOVAQUONE; DECOQUINATE; EXPORTED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICROORGANISM PROTEIN; PROTEIN UIS4; RAPAMYCIN; TORIN; TORIN 1; TORIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HOST PARASITE INTERACTION; LIVER CELL; MEROZOITE; MOUSE; NONHUMAN; PARASITE DEVELOPMENT; PARASITE LOAD; PARASITEMIA; PHENOTYPE; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SPOROZOITE;

HOST-PARASITE INTERACTIONS; MALARIA; P. FALCIPARUM; PROTEIN TRAFFICKING;

ANIMALS; ANTIMALARIALS; LIVER; MEMBRANE PROTEINS; NAPHTHYRIDINES; PLASMODIUM; VACUOLES;

EID: 84880650998     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306097110     Document Type: Article

References (68)

1. Murray CJL, et al. (2012) Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet 379(9814):413-431.
2. O'Brien C, Henrich PP, Passi N, Fidock DA (2011) Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis 24(6):570-577.
3. Prudêncio M, Rodriguez A, Mota MM (2006) The silent path to thousands of merozoites: The Plasmodium liver stage. Nat Rev Microbiol 4(11):849-856.
4. Moradin N, Descoteaux A (2012) Leishmania promastigotes: Building a safe niche within macrophages. Front Cell Infect Microbiol 2:121.
5. Kumar Y, Valdivia RH (2009) Leading a sheltered life: Intracellular pathogens and maintenance of vacuolar compartments. Cell Host Microbe 5(6):593-601.
6. Lingelbach K, Joiner KA (1998) The parasitophorous vacuole membrane surrounding Plasmodium and Toxoplasma: An unusual compartment in infected cells. J Cell Sci 111 (Pt 11):1467-1475.
7. Wang L, Boyer JL (2004) The maintenance and generation of membrane polarity in hepatocytes. Hepatology 39(4):892-899.
8. Bast A, et al. (2011) Defense mechanisms of hepatocytes against Burkholderia pseudomallei. Front Microbiol 2:277.
9. de Koning-Ward TF, et al. (2009) A newly discovered protein export machine in malaria parasites. Nature 459(7249):945-949.
10. Maier AG, et al. (2008) Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell 134(1):48-61.
11. Mueller AK, et al. (2005) Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 102(8):3022-3027.
12. MuellerAK, LabaiedM,Kappe SH,Matuschewski K (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433(7022):164-167.
13. Maier AG, Cooke BM, Cowman AF, Tilley L (2009) Malaria parasite proteins that remodel the host erythrocyte. Nat Rev Microbiol 7(5):341-354.
14. Singh AP, et al. (2007) Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131(3):492-504.
15. Vaughan AM, et al. (2012) Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest 122(10):3618-3628.
16. Hunn JP, Feng CG, Sher A, Howard JC (2011) The immunity-related GTPases in mammals: A fast-evolving cell-autonomous resistance system against intracellular pathogens. Mamm Genome 22(1-2):43-54.
17. Labaied M, et al. (2007) Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 75(8):3758-3768.
18. van Dijk MR, et al. (2005) Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 102(34):12194-12199.
19. Silvie O, Goetz K, Matuschewski K (2008) A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 4(6): E1000086.
20. Aly AS, et al. (2008) Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 69(1): 152-163.
21. Desai SA, Rosenberg RL (1997) Pore size of the malaria parasite's nutrient channel. Proc Natl Acad Sci USA 94(5):2045-2049.
22. Bano N, Romano JD, Jayabalasingham B, Coppens I (2007) Cellular interactions of Plasmodium liver stage with its host mammalian cell. Int J Parasitol 37(12):1329-1341.
23. MacKellar DC, Vaughan AM, Aly AS, DeLeon S, Kappe SH (2011) A systematic analysis of the early transcribed membrane protein family throughout the life cycle of Plasmodium yoelii. Cell Microbiol 13(11):1755-1767.
24. Spielmann T, Fergusen DJ, Beck HP (2003) etramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interface. Mol Biol Cell 14(4):1529-1544.
25. Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Camargo N, Kappe SH (2007) L-FABP is a critical host factor for successful malaria liver stage development. Int J Parasitol 37 (5):483-489.
26. Albuquerque SS, et al. (2009) Host cell transcriptional profiling during malaria liver stage infection reveals a coordinated and sequential set of biological events. BMC Genomics 10:270.
27. Chattopadhyay R, et al. (2011) Early transcriptional responses of HepG2-A16 liver cells to infection by Plasmodium falciparum sporozoites. J Biol Chem 286(30):26396-26405.
28. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293.
29. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2 (67):pe24.
30. Thoreen CC, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284(12): 8023-8032.
31. Prudêncio M, Rodrigues CD, Ataíde R, Mota MM (2008) Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry. Cell Microbiol 10(1): 218-224.
32. Liu Q, et al. (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl) benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem 54(5):1473-1480.
33. Buchholz K, et al. (2011) A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J Infect Dis 203(10):1445-1453.
34. Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38.
35. Van Tyne D, et al. (2011) Identification and functional validation of the novel antimalarial resistance locus PF10-0355 in Plasmodium falciparum. PLoS Genet 7(4): E1001383.
36. Dharia NV, et al. (2009) Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol 10(2):R21.
37. Rottmann M, et al. (2010) Spiroindolones, a potent compound class for the treatment of malaria. Science 329(5996):1175-1180.
38. Vera IM, Beatty WL, Sinnis P, Kim K (2011) Plasmodium protease ROM1 is important for proper formation of the parasitophorous vacuole. PLoS Pathog 7(9):e1002197.
39. Sturm A, et al. (2009) Alteration of the parasite plasma membrane and the parasitophorous vacuole membrane during exo-erythrocytic development of malaria parasites. Protist 160(1):51-63.
40. Kaiser K, Matuschewski K, Camargo N, Ross J, Kappe SH (2004) Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stagespecific proteins. Mol Microbiol 51(5):1221-1232.
41. Doolan DL, et al. (1996) Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. J Biol Chem 271(30):17861-17868.
42. Delves M, et al. (2012) The activities of current antimalarial drugs on the life cycle stages of Plasmodium: A comparative study with human and rodent parasites. PLoS Med 9(2):e1001169.
43. Nam TG, et al. (2011) A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol 6(11):1214-1222.
44. da Cruz FP, et al. (2012) Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis 205(8):1278-1286.
45. Cunha-Rodrigues M, et al. (2008) Genistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategy. PLoS ONE 3(7): E2732.
46. Hobbs CV, et al. (2009) HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis 199(1):134-141.
47. Meister S, et al. (2011) Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334(6061):1372-1377.
48. Gershon PD, Howells RE (1986) Mitochondrial protein synthesis in Plasmodium falciparum. Mol Biochem Parasitol 18(1):37-43.
49. Deponte M, et al. (2012) Wherever I may roam: Protein and membrane trafficking in P. falciparum-infected red blood cells. Mol Biochem Parasitol 186(2):95-116.
50. Crary JL, Haldar K (1992) Brefeldin A inhibits protein secretion and parasite maturation in the ring stage of Plasmodium falciparum. Mol Biochem Parasitol 53(1-2):185-192.
51. Wickham ME, et al. (2001) Trafficking and assembly of the cytoadherence complex in Plasmodium falciparum-infected human erythrocytes. EMBO J 20(20):5636-5649.
52. Nacer A, Berry L, Slomianny C, Mattei D (2001) Plasmodium falciparum signal sequences: Simply sequences or special signals? Int J Parasitol 31(12):1371-1379.
53. Jayabalasingham B, Bano N, Coppens I (2010) Metamorphosis of the malaria parasite in the liver is associated with organelle clearance. Cell Res 20(9):1043-1059.
54. D'Alessandro A, Righetti PG, Zolla L (2010) The red blood cell proteome and interactome: An update. J Proteome Res 9(1):144-163.
55. Brown JR, Auger KR (2011) Phylogenomics of phosphoinositide lipid kinases: Perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol Biol 11:4.
56. Ward P, Equinet L, Packer J, Doerig C (2004) Protein kinases of the human malaria parasite Plasmodium falciparum: The kinome of a divergent eukaryote. BMC Genomics 5:79.
57. Tawk L, et al. (2010) Phosphatidylinositol 3-phosphate, an essential lipid in Plasmodium, localizes to the food vacuole membrane and the apicoplast. Eukaryot Cell 9(10):1519-1530.
58. Vaid A, Ranjan R, Smythe WA, Hoppe HC, Sharma P (2010) PfPI3K, a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the host erythrocyte and is involved in hemoglobin trafficking. Blood 115(12):2500-2507.
59. Oduola AM, Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE (1988) Plasmodium falciparum: Induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol 67(2):354-360.
60. Ritchie GY, et al. (1996) In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. Mol Biochem Parasitol 83(1):35-46.
61. Eastman RT, Dharia NV, Winzeler EA, Fidock DA (2011) Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother 55(8):3908-3916.
62. Korsinczky M, et al. (2000) Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44(8):2100-2108.
63. Barnes DA, Foote SJ, Galatis D, Kemp DJ, Cowman AF (1992) Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 11(8):3067-3075.
64. Baumgartner F, Wiek S, Paprotka K, Zauner S, Lingelbach K (2001) A point mutation in an unusual Sec7 domain is linked to brefeldin A resistance in a Plasmodium falciparum line generated by drug selection. Mol Microbiol 41(5):1151-1158.
65. Elmendorf HG, Haldar K (1993) Identification and localization of ERD2 in the malaria parasite Plasmodium falciparum: Separation from sites of sphingomyelin synthesis and implications for organization of the Golgi. EMBO J 12(12):4763-4773.
66. Cowman AF, Berry D, Baum J (2012) The cellular and molecular basis for malaria parasite invasion of the human red blood cell. J Cell Biol 198(6):961-971.
67. Bullen HE, et al. (2012) Biosynthesis, localization, and macromolecular arrangement of the Plasmodium falciparum translocon of exported proteins (PTEX). J Biol Chem 287(11):7871-7884.
68. Gomes-Santos CS, et al. (2012) Highly dynamic host actin reorganization around developing Plasmodium inside hepatocytes. PLoS ONE 7(1):e29408.